ESCMID*  	ESCMID*  	 NNP	B-NP
guideline  	guideline  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
diagnosis  	diagnosis  	 NN	O
and  	and  	 CC	O
management  	management  	 NN	O
of  	of  	 IN	O
Candida  	Candida  	 NNP	B-NP
diseases  	diseases  	 VBD	I-NP
2012 	2012 	 CD	O
:  	:  	 :	O
prevention  	prevention  	 NN	O
and  	and  	 CC	O
management  	management  	 NN	O
of  	of  	 IN	O
invasive  	invasive  	 JJ	B-NP
infections  	infections  	 NNS	I-NP
in  	in  	 IN	O
neonates  	neonates  	 NN	B-NP
and  	and  	 CC	O
children  	children  	 NNS	O
caused  	caused  	 VBN	O
by  	by  	 IN	O
Candida  	Candida  	 NNP	B-NP
spp  	spp  	 FW	I-NP
Invasive  	Invasive  	 FW	I-NP
candidiasis  	candidiasis  	 FW	I-NP
( 	( 	 -LRB-	O
IC 	IC 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
a  	a  	 DT	O
relatively  	relatively  	 RB	O
common  	common  	 JJ	O
syndrome  	syndrome  	 NN	O
in  	in  	 IN	O
neonates  	neonates  	 NN	B-NP
and  	and  	 CC	O
children  	children  	 NNS	O
and  	and  	 CC	O
is  	is  	 VBZ	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
significant  	significant  	 JJ	O
morbidity  	morbidity  	 NN	O
and  	and  	 CC	O
mortality 	mortality 	 NN	O
.  	.  	 .	O
These  	These  	 DT	O
guidelines  	guidelines  	 NNS	O
provide  	provide  	 VBP	O
recommendations  	recommendations  	 NNS	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
prevention  	prevention  	 NN	O
and  	and  	 CC	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
IC  	IC  	 NNP	B-NP
in  	in  	 IN	O
neonates  	neonates  	 NN	B-NP
and  	and  	 CC	O
children 	children 	 NNS	O
.  	.  	 .	O
Appropriate  	Appropriate  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
prevention  	prevention  	 NN	O
of  	of  	 IN	O
IC  	IC  	 NNP	B-NP
in  	in  	 IN	O
neonates  	neonates  	 NN	B-NP
at  	at  	 IN	O
high  	high  	 JJ	O
risk  	risk  	 NN	O
include  	include  	 VBP	O
fluconazole  	fluconazole  	 NNS	B-NP
( 	( 	 -LRB-	O
A-I 	A-I 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
nystatin  	nystatin  	 NNS	B-NP
( 	( 	 -LRB-	O
B-II 	B-II 	 NNP	B-NP
)  	)  	 -RRB-	O
or  	or  	 CC	O
lactoferrin  	lactoferrin  	 JJ	O
±  	±  	 NNP	O
Lactobacillus  	Lactobacillus  	 NNP	B-NP
( 	( 	 -LRB-	O
B-II 	B-II 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
IC  	IC  	 NNP	B-NP
in  	in  	 IN	O
neonates  	neonates  	 NN	B-NP
is  	is  	 VBZ	O
complicated  	complicated  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
high  	high  	 JJ	O
likelihood  	likelihood  	 NN	O
of  	of  	 IN	O
disseminated  	disseminated  	 JJ	O
disease 	disease 	 NN	O
,  	,  	 ,	O
including  	including  	 VBG	O
the  	the  	 DT	O
possibility  	possibility  	 NN	O
of  	of  	 IN	O
infection  	infection  	 NN	B-NP
within  	within  	 IN	O
the  	the  	 DT	O
central  	central  	 JJ	O
nervous  	nervous  	 JJ	O
system 	system 	 NN	O
.  	.  	 .	O
Amphotericin  	Amphotericin  	 NNP	B-NP
B  	B  	 NNP	I-NP
deoxycholate  	deoxycholate  	 NNS	I-NP
( 	( 	 -LRB-	O
B-II 	B-II 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
liposomal  	liposomal  	 FW	B-NP
amphotericin  	amphotericin  	 FW	I-NP
B  	B  	 NNP	I-NP
( 	( 	 -LRB-	O
B-II 	B-II 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
amphotericin  	amphotericin  	 JJ	B-NP
B  	B  	 NN	I-NP
lipid  	lipid  	 NN	I-NP
complex  	complex  	 NN	I-NP
( 	( 	 -LRB-	O
ABLC 	ABLC 	 NNP	B-NP
)  	)  	 -RRB-	O
( 	( 	 -LRB-	O
C-II 	C-II 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
fluconazole  	fluconazole  	 NNS	B-NP
( 	( 	 -LRB-	O
B-II 	B-II 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
micafungin  	micafungin  	 NNS	B-NP
( 	( 	 -LRB-	O
B-II 	B-II 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
caspofungin  	caspofungin  	 NNS	B-NP
( 	( 	 -LRB-	O
C-II 	C-II 	 NNP	B-NP
)  	)  	 -RRB-	O
can  	can  	 MD	O
all  	all  	 RB	O
be  	be  	 VB	O
potentially  	potentially  	 RB	O
used 	used 	 VBN	O
.  	.  	 .	O
Recommendations  	Recommendations  	 NNS	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
prevention  	prevention  	 NN	O
of  	of  	 IN	O
IC  	IC  	 NNP	B-NP
in  	in  	 IN	O
children  	children  	 NNS	O
are  	are  	 VBP	O
largely  	largely  	 RB	O
extrapolated  	extrapolated  	 VBN	O
from  	from  	 IN	O
studies  	studies  	 NNS	O
performed  	performed  	 VBN	O
in  	in  	 IN	O
adults  	adults  	 NNS	O
with  	with  	 IN	O
concomitant  	concomitant  	 JJ	O
pharmacokinetic  	pharmacokinetic  	 JJ	B-NP
data  	data  	 NNS	I-NP
and  	and  	 CC	O
models  	models  	 NNS	O
in  	in  	 IN	O
children 	children 	 NNS	O
.  	.  	 .	O
For  	For  	 IN	O
allogeneic  	allogeneic  	 JJ	B-NP
HSCT  	HSCT  	 NN	I-NP
recipients 	recipients 	 NNS	I-NP
,  	,  	 ,	O
fluconazole  	fluconazole  	 NNS	B-NP
( 	( 	 -LRB-	O
A-I 	A-I 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
voriconazole  	voriconazole  	 NNS	B-NP
( 	( 	 -LRB-	O
A-I 	A-I 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
micafungin  	micafungin  	 NNS	B-NP
( 	( 	 -LRB-	O
A-I 	A-I 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
itraconazole  	itraconazole  	 NNS	B-NP
( 	( 	 -LRB-	O
B-II 	B-II 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
posaconazole  	posaconazole  	 NNS	B-NP
( 	( 	 -LRB-	O
B-II 	B-II 	 NNP	B-NP
)  	)  	 -RRB-	O
can  	can  	 MD	O
all  	all  	 RB	O
be  	be  	 VB	O
used 	used 	 VBN	O
.  	.  	 .	O
Similar  	Similar  	 JJ	B-NP
recommendations  	recommendations  	 NNS	I-NP
are  	are  	 VBP	O
made  	made  	 VBN	O
for  	for  	 IN	O
the  	the  	 DT	O
prevention  	prevention  	 NN	O
of  	of  	 IN	O
IC  	IC  	 NNP	B-NP
in  	in  	 IN	O
children  	children  	 NNS	O
in  	in  	 IN	O
other  	other  	 JJ	O
risk  	risk  	 NN	B-NP
groups 	groups 	 NNS	I-NP
.  	.  	 .	O
With  	With  	 IN	O
several  	several  	 JJ	O
exceptions 	exceptions 	 NNS	O
,  	,  	 ,	O
recommendations  	recommendations  	 NNS	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
IC  	IC  	 NNP	B-NP
in  	in  	 IN	O
children  	children  	 NNS	O
are  	are  	 VBP	O
extrapolated  	extrapolated  	 VBN	O
from  	from  	 IN	O
adult  	adult  	 NN	B-NP
studies 	studies 	 NNS	I-NP
,  	,  	 ,	O
with  	with  	 IN	O
concomitant  	concomitant  	 JJ	O
pharmacokinetic  	pharmacokinetic  	 JJ	B-NP
studies 	studies 	 NNS	I-NP
.  	.  	 .	O
Amphotericin  	Amphotericin  	 NNP	B-NP
B  	B  	 NNP	I-NP
deoxycholate  	deoxycholate  	 NNS	I-NP
( 	( 	 -LRB-	O
C-I 	C-I 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
liposomal  	liposomal  	 FW	B-NP
amphotericin  	amphotericin  	 FW	I-NP
B  	B  	 NNP	I-NP
( 	( 	 -LRB-	O
A-I 	A-I 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
ABLC  	ABLC  	 NNP	B-NP
( 	( 	 -LRB-	O
B-II 	B-II 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
micafungin  	micafungin  	 NNS	B-NP
( 	( 	 -LRB-	O
A-I 	A-I 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
caspofungin  	caspofungin  	 NNS	B-NP
( 	( 	 -LRB-	O
A-I 	A-I 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
anidulafungin  	anidulafungin  	 NNS	B-NP
( 	( 	 -LRB-	O
B-II 	B-II 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
fluconazole  	fluconazole  	 NNS	B-NP
( 	( 	 -LRB-	O
B-I 	B-I 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
voriconazole  	voriconazole  	 NNS	B-NP
( 	( 	 -LRB-	O
B-I 	B-I 	 NNP	B-NP
)  	)  	 -RRB-	O
can  	can  	 MD	O
all  	all  	 RB	O
be  	be  	 VB	O
used 	used 	 VBN	O
.  	.  	 .	O
